MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management.
Minimed Group stock last closed at $19.80, up 3.61% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Health Information Services industry by N/A percentage points. Minimed Group stock is currently +85.92% from its 52-week low of $10.65, and -18.95% from its 52-week high of $24.43.
There are currently 281.35M shares of MMED outstanding. The market cap of MMED is $5.57B. In the last 24 hours, 23.34M MMED shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy MMED stock.
We believe that eToro is the best stock brokerage. eToro gives you:
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, you need to fill out some personal details so you are able to invest in MMED today.
Now that you have opened your account on the stocks app, your next step is to transfer the money for your investment:
Watch the tutorial below to see the process of transferring money into your brokerage account.
Once you have selected the best place to buy Minimed Group stock, it's very important to evaluate their stock prior to buying, so you actually wrap your head around the risk as well as the opportunity.
WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis.
You can see all of the due diligence checks on MMED's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge MMED's true value.
Using relative valuations methods:
You can do more valuation analysis on MMED's stock here.
Out of 11 Wall Street analysts who give recommendations on MMED, the consensus analyst rating on MMED is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Daniel Markowitz, a top 17% analyst from Evercore ISI Group maintains MMED with a buy rating and raises their MMED price target from $20.00 to $27.00, on Sep 2, 2026.
Larry Biegelsen, a top 16% analyst from Wells Fargo maintains MMED with a strong buy rating and raises their MMED price target from $22.00 to $26.00, on Sep 2, 2026.
Wells Fargo's Larry Biegelsen raised their price target on Minimed Group (NASDAQ: MMED) by 18.2% from $22 to $26 on 2026/09/02. The analyst maintained their Strong Buy rating on the stock.
MiniMed Group reported its Q1 2027 earnings.
Raising their price target, Biegelsen attributed the quarter's revenue beat to a OUS revenue beat and U.S. growth acceleration.
Looking ahead, the analyst noted that:
For Q1 2027, MiniMed Group reported:
For FY 2027, management guided:
CEO Que Dallara commented: "MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline.
"The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth.
"As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value."
Patrick Wood, a bottom 16% analyst from UBS maintains MMED with a strong buy rating and raises their MMED price target from $25.00 to $28.00, on Sep 2, 2026.
Travis Steed, a bottom 13% analyst from Bank of America maintains MMED with a strong buy rating and raises their MMED price target from $24.00 to $28.00, on Sep 2, 2026.
Marie Thibault, a top 18% analyst from BTIG maintains MMED with a strong buy rating and raises their MMED price target from $25.00 to $28.00, on Sep 1, 2026.
You can dive deeper into what analysts are saying on the Minimed Group stock forecast page.
In the last 12 months, insiders at MMED have sold more shares than they have bought.
Que Dallara, CEO of MMED, was the latest MMED insider to sell. They sold $569,002.50 worth of MMED stock on Jul 31, 2026.
Research more about who owns MMED stock here.
No, Minimed Group doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
There are two primary options:
Hit the Open button and eToro will place your order.
If you need more info about buying stocks on eToro, watch the how to video below:
Now that you own some MMED stock, you'll want to stay up-to-date on your stock purchase.
Start a watchlist to keep track of your MMED stock.
To summarize, here are the 6 steps to buy Minimed Group stock:
If you need a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your investment in Minimed Group, click the button below.